An operating bench, not a fund team.
Around 27 people across management, board, scientific advisory and strategic advisors — combining science, clinical, finance, governance and operating experience.
- 27 People
- 4 Disciplines
- 5 PhDs / MDs
- 6 Ex-operators
- 1 Holding company
Scientific diligence, capital deployment, hands-on company building.
The day-to-day operating team. Investment, science, finance, legal and operations — the people closing rounds, sitting on portfolio boards, and steering programs through preclinical and clinical gates.
Anthony Liveris
Anthony has built Proto Axiom into a distinctive company-creation platform — translating breakthrough Australian science into enduring businesses. He previously co-founded Applecart, the New York data and technology company that attracted a US$100M investment from Blackstone Growth.
Lindsay Wu, PhD
Hugh McGonagle
Tony Haddad
John Roach
Charlie Selth
Laura Wimberger, PhD
Richard Wang, PhD
Marina Naidion
Nicholas Hunt, PhD
Diligence, development plans, translational judgement.
The scientists and clinicians who guide our diligence on incoming research and the development plans of portfolio companies — across drug development, regulatory and clinical strategy.
Brian Ledwith, PhD
Sara Althari, PhD
Russell Basser, PhD
William Marshall, MD
Michael Sierra, PhD
Commercial, partnership, capital strategy.
Senior operators advising on commercial, partnership and capital strategy across the platform and its portfolio companies — from Pfizer External Science to GSK and HSBC finance.
Each portfolio company gets working access to a shared bench.
Clinical, regulatory, IP, finance and governance — not as a vendor list, but as a shared resource. The same lawyer who closes our IP licensing also sits in the founder's first board pack. The same regulatory lead who steers our IND filings rotates across companies as their programs hit gates. The same CFO who builds the Series A model is on the line when a clinical site flags a recruitment issue at 7am.
This is what "company creator" means in practice: a permanent operating bench, not a fund. The team is the product.
Operator with biotech experience? Researcher with a translational program?